Tenet Healthcare Corporation (THC)

On our desk, THC's Q2 2026 print is being viewed as a masterclass in operational turnaround. With adjusted diluted EPS soaring 52.2% to $6.12 and consolidated adjusted EBITDA beating expectations at $1.304 billion, the equity story is fundamentally sound. The narrative that they are successfully pivoting toward higher-acuity inpatient services and high-margin outpatient ambulatory surgery through USPI is holding up under close fundamental scrutiny. However, with the stock up over 270% across five years, valuation multiples demand flawless execution going forward.

Looking at the risk factors outlined in the 10-Q and earnings call, we are noting persistent headwinds from declining exchange-market volumes that management explicitly stated will continue for the rest of the year. While hospital adjusted admissions rose 2.6% and revenue per adjusted admission climbed 3.3%, any broader macroeconomic softness hitting commercial revenue or unexpected utilization drops could compress margins from current peaks of 23.2% consolidated adjusted EBITDA.

As a hedge fund PM tracking healthcare services, Tenet's ability to execute early technology-enabled expense management plans—including AI-driven automation and global business center utilization—is separating them from legacy hospital peers. Management is squeezing operational efficiencies out of overhead faster than consensus expected, which explains why margins are expanding even when certain enrollment segments show structural weakness.

In our clinical and operational strategy evaluations, the deliberate shift toward complex orthopedic procedures in the Ambulatory Surgery Center (ASC) setting—evidenced by USPI's 10% increase in same-store total joint replacements—is a major structural advantage. Moving these high-acuity cases out of traditional acute care environments optimizes facility utilization, controls labor overhead, and directly enhances profitability across the ambulatory portfolio.

From our quantitative and modeling perspective, the raised full-year 2026 guidance—lifting revenue projections to between $21.9 billion and $22.5 billion and adjusted EBITDA to $4.83 billion-$5.03 billion—provides a strong upward revision anchor. The improved adjusted free cash flow forecast further supports capital return strategies, though we are watching options skew closely for signs of profit-taking after the recent earnings beat.